Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAFV600E mutation.

American journal of hematology - 1 Aug 2021

Wada Fumiya, Hiramoto Nobuhiro, Yamashita Daisuke, Hara Shigeo, Furukawa Yutaka, Ishii Junko, Nagata Kazuma, Nannya Yasuhito, Ogawa Seishi, Ishikawa Takayuki

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Carbamates
Share to Erdheim-Chester Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Identifiers

PMID: 33971044
DOI: 10.1002/ajh.26232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAFV600E mutation.PMID 33971044Read ↗

Erdheim-Chester disease harboring the BRAF V600E mutation.Semantic proximity Read ↗

Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.Semantic proximity Read ↗

Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.Semantic proximity Read ↗

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.Semantic proximity Read ↗

Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.Semantic proximity Read ↗

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.Semantic proximity Read ↗

Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.Semantic proximity Read ↗

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.Semantic proximity Read ↗

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.Semantic proximity Read ↗

18F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker.Semantic proximity Read ↗

Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale.Semantic proximity Read ↗

Long-term follow-up of mTOR inhibition for Erdheim-Chester diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.